Method for memory B cell-specific differentiation induction, and uses thereof
The present invention relates to a method for memory B cell-specific differentiation induction and to uses thereof and, more specifically, to an anti-CD3 antibody or ligand in a biological sample obtained from and individual, a method for memory B cell-specific differentiation induction comprising a step of treating an anti-CD28 antibody or ligand, and a method for detection a memory B cell which is specific to a specific antigen by using same.
1 . A method for detecting antigen-specific memory B cells in a subject that may have been infected with viruses or bacteria comprising the steps of:
(a) contacting a biological sample obtained from the subject with an anti-CD3 antibody or ligand, and an anti-CD28 antibody or ligand, wherein the biological sample comprises memory B cells and wherein the anti-CD3 antibody or ligand and the anti-CD28 antibody or ligand induce the differentiation of the memory B cells;
(b) contacting the biological sample of step (a) with an antigen; and
(c) detecting an antibody that is secreted by the antigen-specific memory B cells in the biological sample and that specifically binds to the antigen of step (b) wherein the antigen is expressed by the viruses or bacteria which may have infected the subject.
2 . The method of claim 1 , further comprising:
removing CD8 + T cells from the biological sample before contacting the biological sample obtained from the subject with the anti-CD3 antibody or ligand, and the anti-CD28 antibody or ligand in step (a).
3 . The method of claim 1 , wherein the antigen is at least one selected from the group consisting of a Mycobacterium tuberculosis antigen, an anthrax antigen, a Hepatitis A virus (HAV) antigen, a Hepatitis B virus (HBV) antigen, a Hepatitis C virus (HCV) antigen, a human immunodeficiency virus (HIV) antigen, an influenza virus antigen, a Herpes simplex virus (HSV) antigen, a Haemophilus influenzae type b (Hib) antigen, a Neisseria meningitidis antigen, a Corynebacterium diphtheria antigen, a Bordetella pertussis antigen, a Clostridium tetani antigen, a human papilloma virus (HPV) antigen, a Varicella virus antigen, an Enterococci antigen, a Staphylococcus aureus antigen, a Klebsiella pneumonia antigen, an Acinetobacter baumannii -antigent antigen, a Pseudomonas aeruginosa antigen, an Enterobacter antigen, a Helicobacter pylori antigen, a malaria antigen, a Dengue virus antigen, a Middle East Respiratory Syndrome (MERS) virus antigen, a Zika virus antigen, an Orientia tsutsugamushi antigen, a severe fever with thrombocytopenia syndrome Bunyavirus (SFTS Bunyavirus) antigen, a Japanese encephalitis virus antigen, a severe acute respiratory syndrome-corona virus (SARS-CoV) antigen, a severe acute respiratory syndrome-corona virus (SARS-CoV-2) antigen, an Ebola virus antigen, a hepatitis C virus antigen, a hepatitis B virus antigen, an acute respiratory syndrome virus antigen, a West Nile virus antigen, a vesicular stomatitis virus antigen, a Newcastle disease virus antigen, and a pneumococcal antigen.
4 . The method of claim 1 , wherein the detection of the antibody specifically binding to the antigen in step (c) is performed by at least one method selected from the group consisting of enzyme-linked immunospot (ELISPOT), enzyme-linked immunosorbent assay (ELISA), competitive ELISA, a magnetic bead-based assay, and immunochromatography.
5 . The method of claim 1 , further comprising:
determining that the subject has a history of infection with bacteria or viruses expressing the antigen when the antibody specifically binding to the antigen is detected in step (c).
6 . A composition for specifically inducing differentiation of memory B cells using the method of claim 1 comprising an anti-CD3 antibody or ligand; and an anti-CD28 antibody or ligand.
7 . A method for specifically inducing differentiation of memory B cells comprising:
contacting a biological sample obtained from a subject with an anti-CD3 antibody or ligand, and an anti-CD28 antibody or ligand, wherein the biological sample comprises the memory B cells in a subject that may have been infected with viruses or bacteria.
8 . The method of claim 7 , wherein the biological sample is selected from the group consisting of whole blood, peripheral blood mononuclear cells (PBMCs), and combinations thereof.
9 . The method of claim 7 , further comprising:
removing CD8 + T cells from the biological sample before contacting the biological sample obtained from the subject with the anti-CD3 antibody or ligand, and the anti-CD28 antibody or ligand.
10 . The method of claim 7 , wherein the differentiation of the memory B cells is induced to secrete IgG and IgM.